Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
Part of Cancer, Digestive system, Ear, nose & throat, Hormones & metabolism, Lungs & breathing, Mouth & dental clinical trials.
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor or lymphoma diagnosis from biopsy or sample results
- For Phase 1: you either have specific advanced cancer types, or an NTRK1 gene fusion tumor that has come back or stopped responding to standard care
- For Phase 2: your cancer must be TrkA-driven (or NTRK1-positive) in specific cancer types, and have relapsed or not responded to standard care
- Your body must be strong enough for treatment (certain blood counts, liver/kidney levels, and clotting tests within limits) and your energy level must be 0–1
- You must be able to swallow and keep oral medicine down, and you can provide stored tumor tissue or agree to a new tissue sample
- You generally cannot have recent chemo/immunotherapy/radiation or recent investigational drugs, and you must not have certain active heart/lung problems, uncontrolled infections, or pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests VT3989 in people with specific advanced (metastatic or unresectable) cancers. It may help shrink tumors or slow cancer growth in patients who fit the genetic or diagnosis-specific requirements.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This trial tests a combination of two targeted drugs for advanced head and neck cancer that has not responded to standard treatments. It specifically includes patients whose tumors have a change in the CDKN2A gene.
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Hear when a new Head and Neck Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.